Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® (pemetrexed for injection) and Merck’s KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Language: English read more
Publication date: Available online 17 July 2018Source: The Annals of Thoracic SurgeryAuthor(s): Ju-Dong Li, Zi-Long Xiao, Xiao-Xiang Hou
Edgardo S. Santos, MD, FACP, talks about whether Keynote 189 in metastatic non-small cell lung cancer (NSCLC) has impacted his view of PDL-1 expression and patient selection Author: obr Added: 07/17/2018
Condition: Quality of Life Interventions: Combination Product: concurrent chemoradiotherapy (CCRT); Drug: Endostar for one cycle; Drug: Endostar for two cycles Sponsors: Afﬁliated Hospital of North Sichuan Medical College; Jiangsu Simcere Pharmaceutical Co., Ltd. Not yet recruiting
The Society for Immunotherapy of Cancer (SITC) published the first clinical immunotherapy treatment guidelines for non-small cell lung cancer today, providing oncologists and other advance practice...(PRWeb July 17, 2018)Read the full story at https://www.prweb.com/releases/2018/07/prweb15632725.htm
This study aims to identify different expression patterns of fifteen ...
To investigate the incidence of radiation esophagitis (RE) and tumor local control using esophagus sparing technique in locally advanced non-small cell lung cancer (LANSCLC) treated by simultaneous integrated ...
What is the key question?
AbstractLung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment a pproach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for u...
Immunotherapy,Volume 10, Issue 9, Page 797-805, July 2018.